<?xml version="1.0" encoding="UTF-8" ?><rss 
        version         = "2.0"
        xmlns:content   = "http://purl.org/rss/1.0/modules/content/"
        xmlns:wfw       = "http://wellformedweb.org/CommentAPI/"
        xmlns:dc        = "http://purl.org/dc/elements/1.1/"
        xmlns:atom      = "http://www.w3.org/2005/Atom"
        xmlns:sy        = "http://purl.org/rss/1.0/modules/syndication/"
        xmlns:slash     = "http://purl.org/rss/1.0/modules/slash/"
        type            = "0"
                >
        <channel><item post_id='95771'><title>Nasus Pharma gibt Veröffentlichung positiver klinischer Ergebnisse mit intranasalem Epinephrin-Pulverspray FMXIN002 im Journal of Allergy and Clinical Immunology: In Practice bekannt</title><link>https://business24.ch/2023/08/08/nasus-pharma-gibt-veroeffentlichung-positiver-klinischer-ergebnisse-mit-intranasalem-epinephrin-pulverspray-fmxin002-im-journal-of-allergy-and-clinical-immunology-in-practice-bekannt/</link><pubDate>Tue, 08 Aug 2023 08:00:02 +0000</pubDate>		<category><![CDATA[Presseportal]]></category>
		<category><![CDATA[noinjection]]></category>
<guid isPermalink='false'>https://business24.ch/?p=95771</guid><post-id xmlns="com-wordpress:feed-additions:1">95771</post-id></item></channel>
      </rss>